ENTA: Enanta Pharmaceuticals, Inc.
About
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Current Value
$9.341 Year Return
Current Value
$9.341 Year Return
Key Details
Market Cap
$199.60M
P/E Ratio
-1.73
1Y Stock Return
-5.52%
1Y Revenue Growth
-10.71%
Dividend Yield
0.00%
Price to Book
1.3
Strategies that include ENTA
Stock's related to ENTA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SEM | 44.17% | $4.79B | +59.80% | 1.35% |
| ARWR | 43.13% | $2.31B | -34.44% | 0.00% |
| GBIO | 41.14% | $92.84M | +20.87% | 0.00% |
| VIR | 40.82% | $954.40M | -26.51% | 0.00% |
| KROS | 39.46% | $2.17B | +73.87% | 0.00% |
| PLRX | 39.43% | $778.32M | -9.55% | 0.00% |
| VRDN | 38.59% | $1.60B | +28.92% | 0.00% |
| DYN | 38.19% | $3.02B | +182.40% | 0.00% |
| STOK | 37.71% | $614.95M | +197.69% | 0.00% |
| ATNM | 37.28% | $44.30M | -67.05% | 0.00% |
| FATE | 36.72% | $248.29M | -11.02% | 0.00% |
| PGEN | 35.99% | $228.91M | -28.00% | 0.00% |
| KYMR | 35.95% | $2.77B | +125.95% | 0.00% |
| AMGN | 35.79% | $150.48B | +6.52% | 3.20% |
| CRNX | 35.46% | $5.12B | +84.27% | 0.00% |
| MNKD | 35.12% | $1.89B | +84.91% | 0.00% |
| LXRX | 35.06% | $318.44M | -18.44% | 0.00% |
| BYON | 34.87% | $283.64M | -61.81% | 0.00% |
| ZYME | 34.41% | $1.03B | +79.68% | 0.00% |
| KOD | 34.38% | $296.80M | +150.67% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAH | 0.02% | $28.64B | +12.14% | 1.70% |
| WPRT | -0.04% | $76.83M | -36.88% | 0.00% |
| CLLS | 0.04% | $141.30M | -30.99% | 0.00% |
| GOOG | 0.08% | $2.20T | +29.55% | 0.22% |
| WHLM | 0.12% | $17.64M | -29.34% | 0.00% |
| MNR | 0.26% | $1.66B | -10.71% | 15.90% |
| FLG | -0.31% | $4.52B | -59.98% | 0.65% |
| FROG | 0.40% | $3.34B | +11.67% | 0.00% |
| NAT | 0.41% | $636.83M | -30.05% | 13.79% |
| MVO | -0.43% | $106.15M | -22.78% | 16.78% |
| META | 0.43% | $1.42T | +66.51% | 0.27% |
| BACK | -0.45% | $1.76M | -32.90% | 0.00% |
| CPB | 0.48% | $12.96B | +7.08% | 3.40% |
| GOOGL | -0.50% | $2.18T | +30.04% | 0.23% |
| AON | 0.56% | $82.00B | +16.33% | 0.70% |
| BVN | 0.60% | $3.16B | +37.49% | 0.00% |
| GHG | -0.71% | $180.98M | -36.68% | 0.00% |
| TEM | -0.80% | $8.50B | 0.00% | 0.00% |
| FTNT | -0.84% | $69.59B | +72.67% | 0.00% |
| BNED | -0.89% | $277.22M | -91.94% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -12.99% | $21.46B | +15.84% | 1.11% |
| MCK | -11.50% | $78.15B | +35.51% | 0.42% |
| CME | -10.07% | $82.76B | +9.21% | 1.98% |
| NGL | -9.31% | $572.94M | +5.60% | 0.00% |
| TCTM | -9.29% | $8.10M | -42.99% | 0.00% |
| PGR | -7.52% | $149.10B | +57.29% | 0.45% |
| GDDY | -6.70% | $26.31B | +101.81% | 0.00% |
| BEST | -6.25% | $31.65M | +3.88% | 0.00% |
| PULM | -6.22% | $19.83M | +202.98% | 0.00% |
| DMLP | -6.15% | $1.58B | +18.00% | 10.54% |
| RNR | -6.05% | $13.74B | +23.09% | 0.58% |
| SOLV | -5.84% | $11.58B | -16.19% | 0.00% |
| FCN | -5.75% | $7.10B | -10.74% | 0.00% |
| CYCN | -5.47% | $4.77M | -16.19% | 0.00% |
| STNG | -5.41% | $2.96B | +0.87% | 2.75% |
| TH | -5.23% | $839.02M | -24.49% | 0.00% |
| VIRT | -5.19% | $3.17B | +110.38% | 2.60% |
| FWONK | -4.97% | $20.20B | +25.99% | 0.00% |
| TKC | -4.95% | $5.80B | +35.51% | 1.30% |
| XGN | -4.92% | $62.26M | +127.74% | 0.00% |
ETF's related to ENTA
News
Yahoo
Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders should be happy to see the share price up 16% in the last...
Yahoo
We recently published a list of 7 Best Nano Cap Stocks To Invest In. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best nano cap stocks to invest in. What Are the Small Cap Bulls Saying? In one of our recent articles about 8 Most […]
Yahoo
On September 30, 2024, Millennium Management LLC, a prominent hedge fund, expanded its investment portfolio by acquiring 73,1295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA). This transaction, executed at a price of $10.36 per share, marks a significant addition to the firm's holdings in the healthcare sector. The acquisition not only reflects Millennium's strategic investment approach but also highlights its confidence in Enanta Pharmaceuticals' future prospects.
Yahoo
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Yahoo
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
Finnhub
WATERTOWN - Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.